| 鞠放汪青清水汪孟蓉蓉王雅杰△.晚期非小细胞肺癌p53 和ERCC1 表达状态与顺铂为主的
联合方案化疗的近期有效率的相关性研究*[J].,2012,12(5):876-879 |
| 晚期非小细胞肺癌p53 和ERCC1 表达状态与顺铂为主的
联合方案化疗的近期有效率的相关性研究* |
| Association of the Advanced Non-Small Cell Lung Cancer p53 and ERCC1Expression Status with the Short-Term Effect of Combined ChemotherapyRevolved Around Cisplatin |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 顺铂 ERCC1 基因 p53 |
| 英文关键词: Non-small cell lung cancer cisplatin ERCC1 p53 |
| 基金项目:上海市科学技术委员会科研计划资助项目（06DZ19505）；上海市卫生局科研计划项目（2009113） |
|
| 摘要点击次数: 784 |
| 全文下载次数: 967 |
| 中文摘要: |
| 目的：研究晚期非小细胞肺癌不同的p53 和ERCC1 表达状态与基于顺铂为主的姑息化疗近期有效率的相关性。方法：对经
顺铂联合多西他赛或顺铂联合吉西他滨治疗的48 例晚期非小细胞肺癌患者进行回顾性分析，利用既往免疫组化资料，观察基于
顺铂为主的方案近期有效率（RR）的影响因素及化疗不良反应。结果：全组48 例患者均完成至少两周期化疗,并行疗效评价。该组
患者化疗的近期有效率为28 例(58.3% )，RR 与不同的转移病灶部位（P=0.042）及病灶数目（P=0.034）有显著差异。该类方案的近
期有效率与ERCC1 状态（P=0.012）密切相关，而与p53 表达状态（P=0.401）无关。毒性反应主要是骨髓抑制、脱发及消化道反应
等。结论：晚期非小细胞肺癌ERCC1 阴性患者较ERCC1 阳性患者运用顺铂为主的联合方案化疗的近期有效率较高。ERCC1 可
能是顺铂疗效预测的敏感因子。p53 的表达状态可能不是该类方案的疗效预测因子。 |
| 英文摘要: |
| Objective: This study is to explore the correlation of the advanced non-small cell lung cancer p53 and ERCC1 expression
status with the Short-term effect of combined chemotherapy revolved around cisplatin. Methods: After cisplatin combined docetaxel
or cisplatin combined gemcitabine treatment，48 advanced non-small cell lung cancer patients combined past Immunohistochemical data
were analyzed retrospectively. All patients with complete clinical and pathological data were observed as well as the Short-term effect
impact factors of the chemotherapy and chemotherapy adverse. Results: The whole group 48 patients have completed at least two cycles
of chemotherapy, then completed efficacy evaluation. This group of patients of the chemotherapy recent response rate was 28 cases
(58.3% ), RR with different metastatic sites (P=0.042) and the number of Metastasis (P = 0.028) were significantly different. The
chemotherapy Short-term effect is closely related with ERCC1 expression stat us （P=0.034）and not with p53 expression status（P=0.
401）.
Mainly toxicity symptoms were arrest of bone marrow, losing hair and archenteric indisposed. Conclusions: Advanced non-small
cell lung cancer patients with ERCC1-negative have more effective Short-term effect of combined chemotherapy revolved around
cisplatin than ERCC1-positive patients.ERCC1 may predict the efficacy of c isplatin-sensitive factor. The expression of p53 may not be
predictors of the efficacy of cisplatin. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
